Amicus Therapeutics, Inc. (FOLD): Price and Financial Metrics


Amicus Therapeutics, Inc. (FOLD): $11.49

0.06 (+0.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FOLD to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

FOLD POWR Grades

  • Quality is the dimension where FOLD ranks best; there it ranks ahead of 85.36% of US stocks.
  • FOLD's strongest trending metric is Momentum; it's been moving up over the last 179 days.
  • FOLD's current lowest rank is in the Momentum metric (where it is better than 23.68% of US stocks).

FOLD Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for FOLD is 2.44 -- better than 78.03% of US stocks.
  • Of note is the ratio of AMICUS THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; just 20.3% of US stocks have a lower such ratio.
  • With a price/sales ratio of 10.14, AMICUS THERAPEUTICS INC has a higher such ratio than 88.97% of stocks in our set.
  • Stocks that are quantitatively similar to FOLD, based on their financial statements, market capitalization, and price volatility, are APLS, MIRM, GWH, SAGE, and ABSI.
  • Visit FOLD's SEC page to see the company's official filings. To visit the company's web site, go to www.amicusrx.com.

FOLD Valuation Summary

  • FOLD's price/sales ratio is 9; this is 373.68% higher than that of the median Healthcare stock.
  • Over the past 188 months, FOLD's EV/EBIT ratio has gone down 6.2.

Below are key valuation metrics over time for FOLD.

Stock Date P/S P/B P/E EV/EBIT
FOLD 2022-11-01 9.0 16.8 -10.3 -13.0
FOLD 2022-10-31 8.7 16.2 -10.0 -12.5
FOLD 2022-10-28 9.4 17.4 -10.7 -13.4
FOLD 2022-10-27 9.1 16.8 -10.4 -13.0
FOLD 2022-10-26 9.2 17.0 -10.5 -13.2
FOLD 2022-10-25 9.3 17.1 -10.6 -13.2

FOLD Growth Metrics

    Its 5 year net income to common stockholders growth rate is now at -62.48%.
  • The year over year revenue growth rate now stands at 19.14%.
  • Its 4 year cash and equivalents growth rate is now at -34.11%.
Over the past 30 months, FOLD's revenue has gone up $138,908,000.

The table below shows FOLD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 321.145 -168.391 -280.988
2022-03-31 317.827 -188.452 -270.056
2021-12-31 305.514 -202.491 -250.46
2021-09-30 293.931 -181.799 -238.584
2021-06-30 281.823 -200.107 -252.301
2021-03-31 266.763 -197.702 -253.568

FOLD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FOLD has a Quality Grade of C, ranking ahead of 63.39% of graded US stocks.
  • FOLD's asset turnover comes in at 0.333 -- ranking 138th of 680 Pharmaceutical Products stocks.
  • RDUS, CLVS, and NSTG are the stocks whose asset turnover ratios are most correlated with FOLD.

The table below shows FOLD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.333 0.884 -0.273
2021-03-31 0.323 0.884 -0.312
2020-12-31 0.323 0.881 -0.383
2020-09-30 0.308 0.884 -0.458
2020-06-30 0.286 0.886 -0.501
2020-03-31 0.246 0.883 -0.524

FOLD Price Target

For more insight on analysts targets of FOLD, see our FOLD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $16.90 Average Broker Recommendation 1.64 (Moderate Buy)

FOLD Stock Price Chart Interactive Chart >

Price chart for FOLD

FOLD Price/Volume Stats

Current price $11.49 52-week high $12.96
Prev. close $11.43 52-week low $5.91
Day low $11.25 Volume 603,800
Day high $11.64 Avg. volume 3,177,659
50-day MA $10.71 Dividend yield N/A
200-day MA $9.80 Market Cap 3.23B

Amicus Therapeutics, Inc. (FOLD) Company Bio


Amicus Therapeutics is developing treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage disorders. The company was founded in 2002 and is based in Cranbury, New Jersey.


FOLD Latest News Stream


Event/Time News Detail
Loading, please wait...

FOLD Latest Social Stream


Loading social stream, please wait...

View Full FOLD Social Stream

Latest FOLD News From Around the Web

Below are the latest news stories about AMICUS THERAPEUTICS INC that investors may wish to consider to help them evaluate FOLD as an investment opportunity.

Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference

PHILADELPHIA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New York, NY on Wednesday, November 16, 2022 at 9:45 a.m. E.T. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therapeutics Amicus Therapeutics (Nasdaq: F

Yahoo | November 15, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amicus Therapeutics, Inc. - FOLD

NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amicus Therapeutics, Inc. ("Amicus" or the "Company") (NASDAQ: FOLD). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The…

PR Newswire | November 14, 2022

Amicus Therapeutics Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

Amicus Therapeutics ( NASDAQ:FOLD ) Third Quarter 2022 Results Key Financial Results Revenue: US$81.7m (up 2.7% from 3Q...

Yahoo | November 9, 2022

Amicus (FOLD) Gets a Hold from Morgan Stanley

Morgan Stanley analyst Andrew Galler maintained a Hold rating on Amicus (FOLD - Research Report) today and set a price target of $15.00. The company's shares opened today at $10.41.According to TipRanks, Galler is a 3-star analyst with an average return of 4.2% and a 60.00% success rate. Galler covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Amicus, and PTC Therapeutics.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amicus with a $14.33 average price target, a 37.66% upside from current levels. In a report released today, Berenberg Bank also maintained a Hold rating on the stock with a $12.

Austin Angelo on TipRanks | November 8, 2022

Amicus (FOLD) Q3 Earnings Beat, Galafold Sales Miss Estimates

Amicus Therapeutics (FOLD) posts a narrower-than-expected loss in the third quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.

Yahoo | November 8, 2022

Read More 'FOLD' Stories Here

FOLD Price Returns

1-mo 10.69%
3-mo 1.68%
6-mo N/A
1-year 6.39%
3-year 9.07%
5-year -13.80%
YTD -0.52%
2021 -49.98%
2020 137.06%
2019 1.67%
2018 -33.43%
2017 189.54%

Continue Researching FOLD

Here are a few links from around the web to help you further your research on Amicus Therapeutics Inc's stock as an investment opportunity:

Amicus Therapeutics Inc (FOLD) Stock Price | Nasdaq
Amicus Therapeutics Inc (FOLD) Stock Quote, History and News - Yahoo Finance
Amicus Therapeutics Inc (FOLD) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7679 seconds.